Atara Biotherapeutics (ATRA) Net Equity Issued and Repurchased (2013 - 2026)

Atara Biotherapeutics (ATRA) has 13 years of Net Equity Issued and Repurchased data on file, last reported at $3.0 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 17107.69% YoY) and the FY2025 annual result came in at $1.5 million, down 84.26% from the prior year.
• Net Equity Issued and Repurchased climbed to $3.0 million in Q1 2026, from -$25000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $20.5 million in Q1 2022 to a low of -$50000.0 in Q2 2023.
• A 5-year average of $3.4 million and a median of $1.4 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased tumbled 117.39% — and 2024, when it jumped 1364.69%.
• Tracing ATRA's Net Equity Issued and Repurchased over 5 years: stood at $1.4 million in 2022, then advanced by 12.44% to $1.5 million in 2023, then tumbled by 101.68% to -$26000.0 in 2024, then advanced by 3.85% to -$25000.0 in 2025, then surged by 11904.0% to $3.0 million in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $3.0 million (Q1 2026), -$25000.0 (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.